14 Warfarin is superior to aspirin in MI As prophylaxis after thrombolysis There was a 2.5-fold reduction in cardiac events associated with long term warfarin treatment compared with aspirin treatment after acute myocardial infarction (MI) treated with thrombolytics. ' ... Our study is the first major one to present strong evidence for the superiority of warfarin over aspirin. .. ' A retrospective study was conducted on patients discharged after thrombolytic therapy for MI who received either oral aspirin 325mg 1-4 times daily (n = 92), or warfarin adjusted to a prothrombin time of 1.2- l.5 times above the control value (37). 16 of the warfarin recipients also took concomitant aspirin 80 mg/day. Progression to a cardiac endpoint (unstable angina. pulmonary oedema, reinfarction, death) occurred in 39% of the aspirin group and in 16% of the warfarin group, after a mean of 32 and 28 months' follow-up, respectively; events occurred equally in the warfarin and warfarin + aspirin subgroups. There was no major bleeding in either group, although there was a significantly higher frequency of minor bleeding with warfarin than with aspirin (14 vs 1.1 %). Antithrombotic choice was significantly associated with outcome. Schreiber TL. Miller DH. Silvasi D. McNulty A. Zola BE. Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. American Heart Journal 119: 1238-1244. Jun 1990 ,.. 4 Aug 1990 INPHARMA@ ISSN 0156-2703/ 90/ 0804-0014/ OSOI.00/0 © Adi! Ill/mla/iollal L/d

Warfarin is superior to aspirin in MI

Download PDF Report

Upload
hakiet
View
219
Download
2

Embed Size (px)

Citation preview

Page 1: Warfarin is superior to aspirin in MI

Warfarin is superior to aspirin in MI As prophylaxis after thrombolysis

There was a 2.5-fold reduction in cardiac events associated with long term warfarin treatment compared with aspirin treatment after acute myocardial infarction (MI) treated with thrombolytics. ' ... Our study is the first major one to present strong evidence for the superiority of warfarin over aspirin . .. ' A retrospective study was conducted on patients discharged after thrombolytic therapy for MI who received either oral aspirin 325mg 1-4 times daily (n = 92), or warfarin adjusted to a prothrombin time of 1.2-l.5 times above the control value (37). 16 of the warfarin recipients also took concomitant aspirin 80 mg/day.

Progression to a cardiac endpoint (unstable angina. pulmonary oedema, reinfarction, death) occurred in 39% of the aspirin group and in 16% of the warfarin group, after a mean of 32 and 28 months' follow-up, respectively; events occurred equally in the warfarin and warfarin + aspirin subgroups. There was no major bleeding in either group, although there was a significantly higher frequency of minor bleeding with warfarin than with aspirin (14 vs 1.1 %). Antithrombotic choice was significantly associated with outcome. Schreiber TL. Miller DH. Silvasi D. McNulty A. Zola BE. Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. American Heart Journal 119: 1238-1244. Jun 1990 \,,~~

,.. 4 Aug 1990 INPHARMA@ ISSN 0156-2703/ 90/ 0804-0014/ OSOI.00/ 0 © Adi! Ill/mla/iollal L/d